On the fly News and insights, exclusive to thefly.com

ICPT

Intercept

$98.12

1.92 (2.00%)

14:04
09/21/17
09/21
14:04
09/21/17
14:04

Jefferies says Intercept selloff overblown, news is 'largely old'

Jefferies analyst Michael Yee believes the details in today's FDA communication on Ocaliva are largely in line with what was highlighted last week in Intercept Pharmaceuticals' safety patient letter to doctors. "Big picture, this is largely old news and already known," Yee tells investors in an intraday research note. The stock in afternoon trading is down is down $14.18, or nearly 15%, to $83.94. The risk/benefit of Ocaliva still "clearly favors" its use in primary biliary cholangitis patients that have a lack of alternative treatment options, the analyst contends. He views today's stock pullback as overdone and recommends buying Intercept at current share levels. Yee argues the stock currently ascribes no value to the "much larger and valuable" Phase III nonalcoholic steatohepatitis program. The analyst has a Buy rating on the shares with a $275 price target.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.